No abstract

Graph convolutional neural networks (GCNNs) are a powerful extension of deep learning techniques to graphstructured data problems. We empirically evaluate several pooling methods for GCNNs, and combinations of those graph pooling methods with three different architectures: GCN, TAGCN, and GraphSAGE. We confirm that graph pooling, especially DiffPool, improves classification accuracy on popular graph classification datasets and find that, on average, TAGCN achieves comparable or better accuracy than GCN and GraphSAGE, particularly for datasets with larger and sparser graph structures.

Deep learning has led to major advances in fields like natural language processing, computer vision, and other Euclidean data domains. Yet, many important fields have data defined on irregular domains, requiring graphs to be explicitly modeled. One such application is drug discovery. Recently, research has found that using graph neural network (GNN) models, given enough data, can perform better than using humanengineered fingerprints or descriptors in predicting molecular properties of potential antibiotics.We explore these state-of-the-art AI models on predicting desirable molecular properties for drugs that can inhibit SARS-CoV-2. We build upon the GNN models with ideas from recent breakthroughs in geometric deep learning, inspired by the topologies of the molecules. In this poster paper, we present an overview of the drug discovery framework, drug-target interaction framework, and GNNs. Preliminary results on two COVID-19 related datasets are encouraging, achieving a ROC-AUC of 0.72 for FDA-approved chemical library screened against SARS-CoV-2 in vitro.Index Terms-Topology adaptive graph convolutional neural networks, message passing neural networks, GNN, COVID-19, SARS-CoV-2

No abstract

Gaussian graphical models (GGMs) are probabilistic tools of choice for analyzing conditional dependencies between variables in complex systems. Finding changepoints in the structural evo-